Next Article in Journal
Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD
Next Article in Special Issue
RBM10, a New Regulator of p53
Previous Article in Journal
Toxicoproteomic Profiling of hPXR Transgenic Mice Treated with Rifampicin and Isoniazid
Review

The Janus Face of p53-Targeting Ubiquitin Ligases

by 1,†, 2,† and 1,3,4,*
1
Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China
2
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China
3
Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China
4
Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China
*
Author to whom correspondence should be addressed.
Equal contribution.
Cells 2020, 9(7), 1656; https://doi.org/10.3390/cells9071656
Received: 16 June 2020 / Revised: 3 July 2020 / Accepted: 6 July 2020 / Published: 9 July 2020
(This article belongs to the Special Issue p53 Regulation Mechanisms)
The tumor suppressor p53 prevents tumorigenesis and cancer progression by maintaining genomic stability and inducing cell growth arrest and apoptosis. Because of the extremely detrimental nature of wild-type p53, cancer cells usually mutate the TP53 gene in favor of their survival and propagation. Some of the mutant p53 proteins not only lose the wild-type activity, but also acquire oncogenic function, namely “gain-of-function”, to promote cancer development. Growing evidence has revealed that various E3 ubiquitin ligases are able to target both wild-type and mutant p53 for degradation or inactivation, and thus play divergent roles leading to cancer cell survival or death in the context of different p53 status. In this essay, we reviewed the recent progress in our understanding of the p53-targeting E3 ubiquitin ligases, and discussed the potential clinical implications of these E3 ubiquitin ligases in cancer therapy. View Full-Text
Keywords: p53; mutant p53; E3 ubiquitin ligase; tumor suppressor gene; oncogene; cancer therapy p53; mutant p53; E3 ubiquitin ligase; tumor suppressor gene; oncogene; cancer therapy
Show Figures

Figure 1

MDPI and ACS Style

Hao, Q.; Chen, Y.; Zhou, X. The Janus Face of p53-Targeting Ubiquitin Ligases. Cells 2020, 9, 1656. https://doi.org/10.3390/cells9071656

AMA Style

Hao Q, Chen Y, Zhou X. The Janus Face of p53-Targeting Ubiquitin Ligases. Cells. 2020; 9(7):1656. https://doi.org/10.3390/cells9071656

Chicago/Turabian Style

Hao, Qian; Chen, Yajie; Zhou, Xiang. 2020. "The Janus Face of p53-Targeting Ubiquitin Ligases" Cells 9, no. 7: 1656. https://doi.org/10.3390/cells9071656

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop